Results 31 to 40 of about 5,281 (177)

Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease [PDF]

The Permanente Journal, 2018
Hyperuricemia is an independent risk factor for progression of kidney disease.To determine whether lowering serum uric acid level (sUA) to below 6 mg/dL (target) improves mild to moderate chronic kidney disease (CKD) and whether CKD stage influences the benefit of lowering sUA to target.Retrospective epidemiologic cohort study conducted over 8 years ...
Gerald, Levy, Jiaxiao M, Shi, T Craig, Cheetham, Nazia, Rashid   +3 more
openaire   +2 more sources

The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials

Advances in Rheumatology, 2022
Objective The objective was to evaluate whether initiation of urate-lowering treatment (ULT) during an acute gout flare prolonged the current episode.
Ertao Jia, Xiaoling Yao, Hongling Geng, Li Zhong, Jingjing Xie, Yuya Xiao, Yubao Jiang, Xia Qiu, Min Xiao, Yanying Zhang, Dabin Tang, Jiaxin Wei, Jianyong Zhang   +12 more
doaj   +1 more source

Factors associated with initiation and persistence of urate-lowering therapy [PDF]

Arthritis Research & Therapy, 2017
Gout is the most common inflammatory arthritic disease and is caused by crystal deposition secondary to persistent hyperuricemia. Etiological treatment with urate-lowering therapy (ULT) has been available since the 1950s but previous studies have demonstrated suboptimal degree of treatment.
Mats Dehlin, Emin Hoxha Ekström, Max Petzold, Ulf Strömberg, Gunilla Telg, Lennart T. H. Jacobsson   +5 more
openaire   +2 more sources

A Natural Sweetener‐inducible Genetic Switch Controls Therapeutic Protein Expression in Mammals

Advanced Science, EarlyView.
This study develops a natural sweetener, the psicose‐inducible transgene expression (PURE) system based on an Agrobacterium tumefaciens–derived transcriptional repressor PsiR. The PURE system is highly specific to psicose, being insensitive to other sugars and structurally similar molecules.
Longliang Qiao, Zhihao Wang, Shasha Tang, Yuan Fang, Guiling Yu, Xiaoting Qiu, Lingxue Niu, Tao Yan, Xingwan Liu, Xiaoding Ma, Deqiang Kong, Yang Zhou, Ningzi Guan, Jinzhong Tian, Meiyan Wang, Haifeng Ye, Fengfeng Cai   +16 more
wiley   +1 more source

Adherence with urate-lowering therapies for the treatment of gout [PDF]

Arthritis Research & Therapy, 2009
Abstract Introduction Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout.
Harrold, Leslie R, Andrade, Susan E., Briesacher, Becky A., Raebel, Marsha A., Fouayzi, Hassan, Yood, Robert A., Ockene, Ira S.   +6 more
openaire   +3 more sources

Nanozymes for Energy and Environmental Sustainability

Advanced Science, EarlyView.
At present, the widely used nanozymes are oxidoreductase and hydrolase, which have proved to have great application prospects in energy and environment. ABSTRACT Nanozymes have shown remarkable promise in addressing pressing challenges in energy and environmental sustainability.
Xiaoqi Li, Jinxing Chen, Shaojun Dong
wiley   +1 more source

Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases

Clinical Medicine Insights: Cardiology
The association between hyperuricemia and cardiovascular diseases has been studied for many years. Research has shown a link between high uric acid levels and increased risk of including coronary artery disease hypertension and other cardiovascular ...
Franklin Sosa, Mohammed Shaban, Jose Lopez, Gustavo J. Duarte, Swati Jain, Asma Khizar, Timothy Vittorio, Rishabh Mishra, Miguel Rodriguez Guerra   +8 more
doaj   +1 more source

A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations

Терапевтический архив, 2017
The review analyzes in detail the management of gout, which takes into account its onset and course and the presence of comorbidity. Emphasis is placed on drug and non-drug treatments and urate-lowering therapy in patients with kidney dysfunction.
V V Tsurko, M A Gromova
doaj   +1 more source

Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review [PDF]

Journal of General Internal Medicine, 2017
Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of relapse of gouty arthritis, tophi, or urolithiasis. Our main aim was to identify the recurrence of gouty arthritis, tophi, or urolithiasis after discontinuation of ULT.
Beslon, Virginie, Moreau, Perrine, Maruani, Annabel, Maisonneuve, Hubert, Giraudeau, Bruno, Fournier, Jean-Pascal   +5 more
openaire   +4 more sources

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source